Mission statement

This EU Joint Action on Rare Cancers should be viewed as a natural framework for all stakeholders to work together to:

  • prioritise rare cancer, in the agenda of the EU and Member States, with a view to national cancer palns and quality of healthcare, harmonization of clinical practice, innovation through promotion of clinical and translational research;
  • develop innovative and shared solutions, mainly to be implemented through the future ERNs on rare cancers, in the areas of quality of care, research, education and state of the art definition on prevention, diagnosis and treatment of rare cancers.

For the purposes of JARC, the following "families" of RCs will be singed out, following the "Surveilance of rare cancers" (RARECARE - http://www.rarecare.eu) list of rare cancers:

  1. Head and neck cancers (cancers of nasal cavity and sinuses, nasopharynx, hypopharynx, larynx, salivery grands, oropharynx, oral cavity and lip, eye, middle ear)
  2. Thoracic rare cancers (tumours of trachea, thymus, malignant mesothelioma)
  3. Male genital and urogenital rare cancers (tumours of testis, penis, renal pelvis, ureter, urethra and extragonodal germ cell tumours)
  4. Female genital rare cancers (tumours of vulva and vagina, non epithlial tumours of ovary, trophoblastic tumours of the placenta)
  5. Neuroendocrine tumours
  6. Tumours of he endocrine organs (cancers of thyroid, parathyroid, adrenal cortex, pituitary gland)
  7. Central Nervous System tumours (Glial tumours, medulloblastoma, malignant meningioma)
  8. Sarcomas (sort tissue sarcomas, bone sarcomas, gastrointestinal stromal tumours)
  9. Digestive rare cancers (Tumours of small intestine, anal canal, gallbladder and extrahepatic biliary duct)
  10. Rare skin cancers and non-cutaneous melanoma (melanoma of mucosae and of the uvea, adnexal skin carcinomas, Kaposi sarcoma)
  11. Haematological rare malignancies (acute myeloid leukemia, myeloproliferative neoplasms, myelodisplastic and myeloproliferative neoplasms, histiocytic and dendritic cell neoplasms)
  12. Pediatric cancers (all)